News
GSK PLC closed 14.69% below its 52-week high of £17.67, which the company reached on May 31st.
Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...
Zacks Investment Research on MSN3d
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline UpdatesEli Lilly LLY announced plans to acquire SiteOne Therapeutics to expand its pain pipeline. Moderna MRNA announced that the ...
This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...
GSK PLC closed 18.99% short of its 52-week high of £17.88, which the company achieved on May 28th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback